Le Tourneau C - Search Results

1

Precision cancer medicine: Concepts, current practice, and future developments.

Edsjö A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabières C, Ploeger C, Lassen U, Le Tourneau C, Lehtiö J, Ott PA, von Deimling A, Fröhling S, Voest E, Klauschen F, Dienstmann R, Alshibany A, Siu LL, Stenzinger A. Edsjö A, et al. Among authors: le tourneau c. J Intern Med. 2023 Oct;294(4):455-481. doi: 10.1111/joim.13709. Epub 2023 Aug 28. J Intern Med. 2023. PMID: 37641393 Review.

2

Molecular targeted therapy of head and neck cancer: review and clinical development challenges.

Le Tourneau C, Faivre S, Siu LL. Le Tourneau C, et al. Eur J Cancer. 2007 Nov;43(17):2457-66. doi: 10.1016/j.ejca.2007.08.016. Epub 2007 Sep 27. Eur J Cancer. 2007. PMID: 17904355 Review.

3

Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.

Le Tourneau C, Siu LL. Le Tourneau C, et al. Curr Opin Oncol. 2008 May;20(3):256-63. doi: 10.1097/CCO.0b013e3282f9b575. Curr Opin Oncol. 2008. PMID: 18391623 Review.

4

Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.

Le Tourneau C, Vidal L, Siu LL. Le Tourneau C, et al. Drug Resist Updat. 2008 Jun;11(3):99-109. doi: 10.1016/j.drup.2008.04.001. Epub 2008 Jun 2. Drug Resist Updat. 2008. PMID: 18515176 Review.

5

Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.

Le Tourneau C, Siu LL. Le Tourneau C, et al. Expert Opin Investig Drugs. 2008 Aug;17(8):1247-54. doi: 10.1517/13543784.17.8.1247. Expert Opin Investig Drugs. 2008. PMID: 18616420 Review.

6

Dose escalation methods in phase I cancer clinical trials.

Le Tourneau C, Lee JJ, Siu LL. Le Tourneau C, et al. J Natl Cancer Inst. 2009 May 20;101(10):708-20. doi: 10.1093/jnci/djp079. Epub 2009 May 12. J Natl Cancer Inst. 2009. PMID: 19436029 Free PMC article. Review.

7

Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.

Le Tourneau C, Michiels S, Gan HK, Siu LL. Le Tourneau C, et al. J Clin Oncol. 2009 Dec 10;27(35):5965-71. doi: 10.1200/JCO.2009.22.3685. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805677 Review.

8

Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.

Le Tourneau C, Stathis A, Vidal L, Moore MJ, Siu LL. Le Tourneau C, et al. J Clin Oncol. 2010 Mar 10;28(8):1401-7. doi: 10.1200/JCO.2009.25.9606. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124167 Review.

9

Molecular targeted therapies in all histologies of head and neck cancers: an update.

Razak AR, Siu LL, Le Tourneau C. Razak AR, et al. Among authors: le tourneau c. Curr Opin Oncol. 2010 May;22(3):212-20. doi: 10.1097/CCO.0b013e328338001f. Curr Opin Oncol. 2010. PMID: 20173639 Review.

10

Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.

Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, MacLean M, Nayyar R, Tusche MW, Metser U, Wright JJ, Mak TW, Siu LL. Quintela-Fandino M, et al. Among authors: le tourneau c. Mol Cancer Ther. 2010 Mar;9(3):751-60. doi: 10.1158/1535-7163.MCT-09-0868. Epub 2010 Mar 2. Mol Cancer Ther. 2010. PMID: 20197396 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

262 results

Search Page